Phosphagenics Limited is developing a skin gel that administers insulin. They are currently testing the effect of long-acting insulin in the patented formula.

Research has demonstrated that a single application of the insulin gel rapidly delivered insulin into the bloodstream without any adverse reactions. Additionally, it significantly lowered blood glucose, insulin and c-peptide levels.

The company has been working on improving drug effectiveness and cost efficiency through a process called phosphorylation. Many enzymes and receptors are switched "on" or "off" by phosphorylation, including the glucose lowering properties of insulin. Once inside the skin -- enzymes activate these properties, impacting the blood sugar. This does not cause irritation to the skin, allows for a sustained release of medication in just one application, begins to take effect within an hour of application, can be used with many forms of prescriptions (small and large molecule medicines), and is economical to produce.

If it significantly reduced c-peptide levels, this might be more appropriate for type 2 diabetics - for a temporary basis. Judging by numbers, majority rules and since 80% of diabetics are type 2...this could be a feather in the capitalists cap for pain-free insulin delivery. However, if blood sugar control becomes as easy as a handi-wipe, how motivated will anyone be to eat right and exercise? Wash your hands for dinner, please.

In 1996 a 41 year old male (a type 1 diabetic for 18 years) was injected with biocapsules containing pig islets to regulate his blood sugar level. The transplanted cells helped reduce the patient's insulin requirement by 34% for over a year, which provided better control. By 2005 the patient's glycated hemoglobin levels (HbA1c) remained lower than the pre-transplant levels.

Ten years later, the patent contacted Living Cell Technologies to inform them that he believed the transplanted pig islets were still alive and well. After tests were conducted, it was concluded that the pig cells were (as he reported) still functioning. This proved that the LCT patented technology for xenotransplantation was effective. It allows the islets to survive at least ten years in a micro-capsule coating and continue to release insulin into the patient's bloodstream without immune suppression. After tests we conducted on the type of insulin present in the patients blood - it was with 100% certainty that it was pig and not human insulin.

LCT has significantly advanced the encapsulation process since the 1996 clinical trial and there is an even greater understanding and control over the longevity and robustness of the encapsulation process, as well as the porcine islet cells. LCT will be trialing the DiabeCell pig islet cell transplant in patients in a phase I/IIa clinical trial, expected to begin in Quarter 2, 2007. In addition, LCT is awaiting approval to conduct an additional trial in New Zealand this year with a different treatment protocol. Subsequent trials in the US or Europe are intended following initial results from these studies.

If overseas trials are coming through with flying colors - why aren't we doing this yet? C'mon USA - where's your competitive spirit? All these pigs up in Spring Point might be put to good use, after all. Oink Oink.